Brought to you by 
Intrexon gets $50mm through late-stage round
27 Jan 2012
Executive Summary
Intrexon Corp. (molecular biology for life science applications) raised $50mm through a late-stage financing to 42 undisclosed investors. The company's last fund-raise was a $100mm Series E round in May 2011.
Deal Industry
- Research, Analytical Equipment & Supplies
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Transgenics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Intrexon gets $50mm through late-stage round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice